Author: Dr. David Lowemann

Trial Finds Wegovy Improves Liver Fibrosis

Novo Nordisk said on Friday its weight-loss drug met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis. The trial, which studied 2.4 milligram dose of semaglutide, showed a statistically significant improvement… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is a […]

Published on November 1, 2024

Low-level lead poisoning is still pervasive in the US and globally

Chronic, low-level lead poisoning is a major risk factor for cardiovascular disease in adults and cognitive deficits in children, even at levels previously thought to be safe, Low-level lead poisoning is a risk factor for preterm. Annually 5.5 million deaths from cardiovascular disease attributed to low-level lead poisoning; accounts for a loss of 765 million […]

Published on November 1, 2024

The dangerous pursuit of muscularity in men and adolescent boys

Men and adolescent boys are increasingly at risk of resorting to the dangerous use of anabolic steroids in a bid to achieve the desired muscular build modeled on social media, warn body image experts. A new review that focused specifically on men found that exposure to social media posts depicting ideal muscular male bodies is […]

Published on November 1, 2024